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ABSTRACT 
Classical swine fever (CSF) is a viral infectious disease mainly affecting wild boars 
and captive pigs. Being highly contagious and lethal, an outbreak causes both tremendous 
direct economic loss and financial burden before a new round of production. The disease 
has been long endemic in Asia, Central and South America, Africa and some regions in 
Europe, while many developed countries including the US, Canada, Australia, New 
Zealand and several members of the European Union have taken strict measures to 
successfully eradicate it. Vaccines currently available can protect pigs throughout their 
economic life, however, countries without endemics choose to not them for the concern 
of stamping out policy since no sophisticated marker vaccines together with companion 
tests fulfilling DIVA (differentiation of infected from vaccinated animals) criterion are 
approved yet. 
The causative agent is classical swine fever virus (CSFV), under the family 
Flaviviridae and genus Pestivirus. Viral particle is 40-60 nm in diameter, containing 
icosahedral nucleocapsid and its genome is single stranded positive-sense RNA (~12.5 
kb). Lipid bilayer envelope is anchored with three viral proteins: Erns, E1 and E2 among 
which E2 is the most immunogenic and induces strong antibody response in hosts. 
Several approaches are currently available for CSFV diagnosis: (i) detection of 
CSFV, and (ii) detection of CSFV specific antibody. Identifying the existence of virus 
particle or necropsy is labor-intensive and not suitable for high throughput screening in 
the event of which ELISA-based test is preferred for detecting virus specific antibodies. 
 x 
This research project is aimed at modifying a widely used commercial ELISA to serve as 
a companion test for a previous marker vaccine candidate with the intention of 
discriminating CSFV naturally infected from vaccinated pigs. 
Baculovirus/insect cell protein expression system has been long practiced and proved 
an effective way to biosynthesize recombinant proteins. Sequences encoding foreign 
protein can be easily incorporated into recombinant baculoviruses using commercially 
available kits. In this research, a recombinant baculovirus was constructed and used to 
infect Sf9 cells to synthesize genetically modified viral envelope glycoprotein E2 which 
plays a key role in the ELISA-based test. 
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CHPATER 1 
INTRODUCTION 
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1.1 CSF: Introduction 
 The first record of hog cholera which is now known as classical swine fever was 
presumably in 1833 in Ohio, USA, one of many outbreaks during that time as claimed by 
Hanson (Hanson, 1957). However, the disease has been suspected to be transmitted from 
Europe since a similar one was documented in 1822, France (Birch 1992; cited byCole et 
al., 1884). Falling into the OIE (World Organization for Animal Health) list, it is required 
that any infection cases be reported so that elimination of pigs and other measures can be 
taken to control spread. The disease can almost be considered the most economically 
significant one affecting pig industry, leading to tremendous loss once an outbreak is 
confirmed. Despite being widespread in both Europe and the US, till the 1860s, many 
developed countries including America, Canada, Australia, New Zealand and some 
members of the European Union have successfully eradicated the endemic of CSF with 
strict actions such as the stamping out policy. However, the disease is still a big concern 
in many parts of Asia, Central and South America, Africa and several countries in 
Europe. Therefore, risk of transmission to and causing outbreaks in nations without such 
endemic disease does exist since those countries do not adapt routine vaccines against 
CSFV. 
 
1.2 Disease 
 Classical swine fever is mostly seen transmitted oronasally, while transmission via 
fomite or skin wound is possible. Transplacental infection was also reported (Oirschot & 
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Terpstra, 1977). Many factors including viral virulence, age and breed of infected swine, 
etc., (Depner et al., 1997; Moennig & Plagemann, 1992; Van Oirschot, 1999) contribute to 
severity and disease related signs which are characteristically exhibited by pyrexia, 
hemorrhage of the outer skin and mucosae and central nervous system disorders (Moennig, 
2000). Mortality rate among young pigs is especially high, being around 90%-100% and 
death can occur two to three weeks after initiation of acute infection. Prenatal infection of 
sows may lead to abortion, stillbirth, malformations and persistently viremic piglets 
(Meyer, Liess, Hermanns, & Trautwein, 1980). 
 Density of pig population is largely related to the risk of disease transmission and a 
potential outbreak. Some regions adapt the intensification pattern of producing pigs to a 
large-scale while others prefer to raise them in small-sized farms. Despite the high 
concentration in mass pig production, it is relatively easier to regulate and perform quality 
control. Pigs in small private farms may be confronted with less risk of cross infection, but 
the general management and surveillance of these farms are more difficult to conduct. 
Infected wild boars or feral pigs can, if having contact with, transmit virus to domestic pigs 
both in a direct and indirect (fomite transmission) way. 
 
1.3 Disease Control 
 Effective control of CSFV requires establishment of epidemiological work, e.g. 
investigation and tracking of each outbreak and performing virus isolate typing (Greiser-
Wilke, Depner, Fritzemeier, Haas, & Moennig, 1998; Greiser-Wilke, Zimmermann, 
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Fritzemeier, Floegel, & Moennig, 2000; Paton, McGoldrick, Greiser-Wilke, et al., 2000). 
Apart from a well-developed understanding of epidemiological situation, an accurate and 
efficient laboratory diagnosis is indispensable. Modern molecular approaches have been 
utilized for screening from two perspectives: (i) detection of virus, and (ii) detection of 
virus specific antibodies. 
To detect the presence of viral particles, isolation of virus in cell culture is still the 
‘gold standard’. Ongoing viremia is required for the isolation of CSFV from animal spleen, 
tonsils, lymph nodes, parotid glands and kidneys (Anonymous, 1980, 1996). Isolated virus 
is then grown in susceptible cell lines of porcine to be tested with CSFV specific 
monoclonal antibodies (Anonymous, 1980, 1996; Cay et al., 1989). Two less sensitive tests 
are adapted instead for the purpose of reducing labor work:  in situ antigen demonstration 
with fluorescent antibody and ELISA targeting specific CSFV antigens. Furthermore, 
detection of viral RNA by RT-PCR and following sequencing have become an alternative 
(Greiser-Wilke et al., 1998; Hofmann, Brechtbühl, & Stäuber, 1994; Lowings, Ibata, 
Needham, & Paton, 1996; Paton, McGoldrick, Belak, et al., 2000).  
Serological test is also favored given its rapidness and sensitivity. Virus neutralization 
tests are designed for CSF antibody detection in which case serum is mixed with CSF 
reference virus so that neutralizing reaction occurs in the presence of antibody. However, 
antibodies generated against ruminant pestivirus may cross-react with CSF reference virus 
thus a second ruminant pestivirus neutralizing test is required for differentiation. In large-
scale screening, ELISA tests targeting CSFV specific antibody in serum are more accepted 
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owing to its convenience. Samples tested positive or ambiguous should be processed with 
neutralization test again to confirm that they are not fake positive. 
There have been many trails to develop CSF vaccines since 1940s. The first attempt 
to attenuate CSFV (Baker, 1946; Koprowski, James, & Cox, 1946) was not initially 
successful but eventually led to safe and efficacious vaccines. China-strain (C-strain) based 
attenuated vaccine is the most widely accepted and used to protect domestic pigs as well 
as wild boars from CSF. It is attenuated by adapting in rabbit and can still promote potent 
antibody response which protects pigs from virulent CSFV infection as early as five-day 
post vaccination. This vaccine is also highly safe and can be given to pregnant animals. 
However, such vaccine does not fulfill DIVA (differentiation of infected from vaccinated 
animals) criterion since both types of animals exhibit the same pattern of antibody 
response. 
 Therefore, a marker vaccine is needed. E2 subunit vaccine was designed aiming at 
only inducing antibody response against viral glycosylated envelope protein E2 in 
vaccinated animals, while naturally infected animals generate many more classes of 
antibodies including those against viral envelope protein Erns. Therefore, detection of 
antibody with high affinity for Erns indicates infection. However, subunit vaccines are less 
immunogenic and protection of E2 subunit vaccine is not substantial until 21 dpv. 
Additionally, sensitivity of ELISA test designed for detection of Erns specific antibodies is 
low. Live attenuated marker vaccine is a more promising option given higher 
immunogenicity and potent protection. A successful practice FlagT4G vaccine (Holinka et 
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al., 2014) proven to be capable of inducing effective protection against CSFV challenge as 
early as 7 dpv. Two markers are involved in the vaccine: (i) a positive marker, Flagâ 
epitope, inserted in E1 glycoprotein, and (ii) a mutation introduced into the WH303 epitope 
in E2 glycoprotein (wild type: TAVSPTTLR to mutant: TSFGMDTLR). Positive detection 
of antibody against Flagâ epitope and simultaneous negative detection of antibody against 
TAVSPTTLR epitope indicates vaccination, while presence of TAVSPTTLR epitope 
specific antibodies is interpreted as infection. 
 Countries with and without endemics of CSF take rather different control policies. The 
former adapts a routine of vaccination which protects pigs throughout their economic lives 
and only pigs showing clinical signs will be eliminated, but the possibility of virus being 
hidden from screening cannot be ruled out. As a result, their meat product is not accepted 
for importing by those countries without CSF occurring. In regions where no CSF endemic 
exists, governments conduct a stamp-out policy for both herds with infected pigs and 
neighboring herds, including epidemiological investigations, clinical diagnosis, tracking 
and restriction for movement of live pigs, meat product and vectors with potential 
capability of transmitting virus, etc. (Anonymous, 1980; Edwards et al., 2000) Death 
caused by CSFV related symptoms actually only accounted for a small proportion, the 
majority of pigs were killed out of disease control purpose and such eradication led to 
severe economic loss.  
 
1.4 CSFV: Introduction 
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 Classical swine fever virus is a spherical enveloped particle of 40 to 60 nm in 
diameter, the icosahedral nucleocapsid of which contains 12.3 kb single stranded RNA 
genome with positive polarity. The virus belongs to the pestivirus genus of the 
Flaviviridae family (Wengler, 1991) and is closely related to other two viruses in the 
same genus: bovine viral diarrhea virus (BVDV) and border disease virus (BDV) of 
sheep. Viral infectious cDNAs have been successfully produced by some laboratories 
(Meyers, Thiel, & Rümenapf, 1996; Moormann, Van Gennip, Miedema, Hulst, & Van 
Rijn, 1996; Ruggli, Tratschin, Mittelholzer, & Hofmann, 1996). Four structure proteins: 
core protein C, envelope glycoproteins Erns, E1, E2 and seven non-structural proteins: p7, 
NS2, NS3, NS4A, NS4B, NS5A, NS5B are encoded in the viral genome (Beer, Reimann, 
Hoffmann, & Depner, 2007; Elbers et al., 1996; Meyers & Thiel, 1996). Viral 
glycoprotein E2 is the main virulence determinant and is responsible for attachment and 
invasion to host cells. Being highly immunogenic, E2 is the main target of neutralizing 
antibody and cytotoxic T cell response. Stable existence of virus usually occurs in humid 
animal excretion and fresh meat product (Savi, Torlone, & Titoli, 1965), but inactivation 
of virus can be easily achieved by damaging viral envelope and nucleocapsid with heat, 
detergent, lipid solvent, protease and disinfectants (Edwards et al., 2000).  
 
1.5 CSFV Pathogenesis 
 Classical swine fever virus preferentially infects endothelial cells, some epithelial 
cells, lymphoreticular cells and macrophages (Moennig, 2000). Gestation period infection 
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causes abnormal tissue and organ differentiation and maturation in fetus. Postnatally 
infected pigs may develop thrombosis, endothelial damage due to the invasion of virus 
into such host cell types. These lesions are usually accompanied with hemorrhage or 
petechial bleeding. Pulmonary as well as bronchial epithelial cells infected by CSFV may 
lose normal physiological function to a degree where bronchopneumonia occurs. Central 
nervous system disorders are presumably resulted by infection of cerebrovascular 
endothelial cells and thrombosis given severe vasculitis concomitantly observed with 
encephalitis. Depletion of B cells in peripheral blood and lymphoid tissues was reported 
in the very late phase of acute infection (Susa, König, Saalmüller, Reddehase, & Thiel, 
1992). Antibody response against CSFV may protect pigs up to years or even throughout 
entire life (Van Oirschot, 1999). Neutralizing antibody can be detected as early as 11-day 
post infection and remain high level up to 100 dpi with data support. In the case of 
chronic infection, neutralizing antibody may only be detectable in the few days after 30 
dpi (Cheville & Mengeling, 1969; Depner, Rodriguez, Pohlenz, & Liess, 1996). 
Prenatally infected pigs which develop persistent viremia hardly generate CSFV specific 
antibodies (Van Oirschot, 1999). Postnatal piglets are protected by passive immunity 
including maternal antibodies of which the half-life is about two weeks, however, virus is 
still capable of replicating and shedding under such circumstance. T cell immunity in 
defense of CSFV is comparatively less elucidated.  
 We realized that the closely related virus BVDV is less virulent than CSFV and when 
their E2 protein coding sequences were aligned, significant difference was only observed 
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within the WH303 epitope. Because our previous few attempts to attenuate the CSFV by 
arbitrarily introducing mutations into the WH303 epitope ended up being lethal to the 
virus, we then only replaced the amino acid within the WH303 epitope of CSFV E2 
protein with that of BVDV correspondingly. Starting from the first amino acid alanine, 
when all five were mutated (AVSPT to SFGMD), the virus was fully attenuated but it 
could still elicit strong and protective immune response in pigs. This phenomenon 
indicates the WH303 epitope plays an important role in viral reproduction as well as 
pathogenesis. 
 
1.6 Baculovirus/Insect Cell Protein Expression System  
 Many insect cell lines have been exploited for expression of heterologous proteins 
including Bombyx mori, Mamestra brassicae, Spodoptera frugiperda, Trichoplusia ni, 
and Drosophila melanogaster among which Spodoptera frugiperda SF9 cell might be the 
most commonly chosen one. The ability to undergo posttranslational modification e.g., 
glycosylation, grants insect cells superiority to prokaryotic cell in many recombinant 
protein expressions especially those required to be similar to mammalian proteins. 
Additionally, the convenience, effectiveness and safety of this approach and the fact that 
numerous protein products on market are manufactured in this way may strongly support 
the advantages of insect cell protein expression system. 
 Recombinant baculovirus serves as the vector carrying the foreign genes and 
Autographa californica multiple nuclear polyhedrosis virus particularly infects Sf9 cells 
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(Davies, 1994; Shuler & Shuler, 1995). The genome of baculovirus is double-stranded, 
circular, supercoiled DNA. The life cycle of wild-type baculovirus includes two forms, the 
ODV (occlusion derived virus) and BD (budded virus), however, the recombinant 
baculovirus loses the polyhedrin gene which is replaced by a foreign gene of interest. Three 
typical phases: early, late and very late phase are involved in wild-type virus infection cycle. 
In early phase (0-6 hours), virus attaches to, invades host cell, initiates early viral gene 
expression and interferes with host gene expression. During late phase (6-24 hours), viral 
DNA is replicated and genes responsible for assembly are expressed to form and release 
budded viral particles. Very late phase (24-96 hours) is marked by formation of ODVs and 
cell lysis. Recombinant baculovirus does synthesize polyhedrin coat of ODV, but foreign 
gene is expressed instead. Cytopathic effects are less noticeable which are merely reflected 
by, if grown in T-75 flask, increased cell diameter and enlarged nuclei in the early phase, 
cessation of cell growth and dislodgment in late phase as well as cell lysis in very late 
phase. 
 
1.7 Significance and Rationale 
 ELISA targeting CSF specific antibody has been widely used as an approach for CSF 
disease screening due to its convenience and high through-put. In particular, countries 
without endemics of CSF including the US adapt a non-vaccine policy in the event of 
which detection of CSFV specific antibody in serum means elimination of these animals 
has to be implemented, leading to tremendous economic loss. However, a marker vaccine 
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and its companion test may exempt healthy vaccinated animals from elimination. In order 
to promote the potential wide acceptance and application of a previous CSF live 
attenuated marker vaccine candidate, a companion serological test fulfilling DIVA 
criterion is urgently needed. 
 The double-antigenic live attenuated CSF FlagT4G virus (FlagT4Gv) (Holinka et al., 
2014) contains two modifications critical for DIVA purpose one of which is the mutation 
in WH303 (mAbWH303) epitope (TAVSPTTLR to TSFGMDTLR) in E2 glycoprotein. 
Due to the absence of antibody binding WH303 epitope in vaccinated pigs, CSFV 
naturally infected pigs can be discriminated serologically by detecting the presence of 
such antibody. Thus, we hypothesize to modify a commercially available ELISA (IDEXX 
CSFV Ab Test) to produce a double-competition assay to fulfill this mechanism and 
differentiate infection from vaccination. 
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2.1 Approach to fulfilling DIVA criterion 
 Here we propose to discriminate CSFV naturally infected from vaccinated pigs using 
a double-competition ELISA by detecting a subclass of antibodies which is only present 
in sera of infected pigs. Wild type CSFV envelope glycoprotein E2 contains a typical 
epitope TAVSPTTLR (amino acid sequence), the immunogenicity of which is rather high 
that majority of CSFV specific antibodies generated by infected pigs is against this 
epitope. However, a previously developed marker vaccine candidate has a mutation that 
epitope TAVSPTTLR is replaced by TSFGMDTLR, leading to vaccinated animals 
lacking of antibodies against TAVSPTTLR epitope. By incubating sera with a 
recombinant peptide termed E2T4G that is identical to the wild type E2 protein except for 
the absence of WH303 epitope, antibodies generated by infected pigs remain dissociative 
thus being detected by the IDEXX ELISA.  
 
2.2 Hypothesis 
 The failure to distinguish between naturally infected and FT4G vaccinated pigs using 
the commercially-available IDEXX ELISA is due to the inability of conjugates to bind in 
the presence of irrelevant antibodies against non-WH303 epitopes in E2 protein. 
 Recombinant protein E2T4G can sequester irrelevant antibodies and enrich anti-303 
antibodies, thus making the difference distinguishable. 
2.3 Specific aims 
 1. Biosynthesize genetically modified viral envelope glycoprotein E2 (E2T4G) with 
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baculovirus/insect cell protein expression system. 
 2. Interfere commercial ELISA with E2T4G to enrich antibodies that are merely 
present in sera from naturally infected pigs. 
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3.1 Introduction 
 Baculovirus/insect cell protein expression system has been long practiced to 
successfully produce recombinant proteins. In this research, recombinant baculovirus 
encoding genetically modified viral envelope glycoprotein E2 (E2T4G) was constructed, 
amplified, titrated and stocked at 4 ℃. Sf9 cells were grown firstly in a monolayer then 
suspension culture was adapted for the purpose of reducing consumption, labor work, 
contamination risk and increasing cell viability. The recombinant protein E2T4G is not 
secretory but loses the transmembrane domain so that extraction is simply by adding lysis 
buffer and high-speed centrifugation. The loss of such transmembrane domain will also 
lead to a decreased molecular weight compared to the approximate 55 kDa of the wild 
type viral E2 protein. Anti-his-tag Western blot was performed to identify the presence of 
E2T4G in clarified cell lysate followed by cobalt column purification, desalting, BCA 
assay and on-chip electrophoresis. Protocols and conditions had been explored to achieve 
high protein expression and to reduce unnecessary loss during extraction and purification. 
 
3.2 Materials and methods 
Cell culture    Sf9 cells were purchased from Invitrogenâ and preserved at -80℃ at a 
concentration of 1*106 cell/ml. Gibco Grace’s Medium (1X) was supplemented with 20% 
heat inactivated FBS (RMBI). Gentamicin (SIGMA) was added to a final concentration 
of 0.05 mg/ml. To initiate an adherent culture, Sf9 cells were thawed at room temperature 
and mixed with 10 ml of growth media before centrifugation for 5 min at 1000 rpm. 
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Cellular pellet was suspended with 6 ml of media and transferred to a T-25 flask, growing 
at 27℃. 24 hours after inoculation, media was replaced with fresh ones to remove any 
remaining DMSO. Cells were scraped down and transferred to a T-75 flask when 
confluency reached 100% and volume of medium used in a T-75 was 15 ml. To start a 
culture in suspension, Sf9 cells were taken from a T-75 flask with 100% confluency and 
added to a 250-ml conical glass flask to reach a concentration of 1*106 cell/ml in a total 
volume of 30 ml. 300 ul pluronicâ (GIBCO, 10%) was added to protect cells from shear 
force at the shake speed of 125 rpm. Growth state was monitored daily by counting using 
hemocytometer and trypan blue staining. Culture was expanded to a 500-ml conical flask 
under the circumstance that viability was no lower than 90% and concentration reached 
2*106 cell/ml. 
 
Baculovirus construction    Recombinant baculovirus was constructed on the basis of 
site-specific recombination with the Gatewayâ Technology of Invitrogen. DNA sequence 
of recombinant viral envelope glycoprotein E2 (E2T4G) was synthesized into a bacmid 
containing two att recombinant sites by GENEWIZ. Recombination was performed 
following manufacturer’s protocol (BaculoDirect™ Baculovirus Expression System, 
Invitrogen). Virus passage III was titrated and stocked at 4 and -80℃.	 
 
Infection and harvest    Sf9 cells in monolayer were infected with a MOI of 0.1~5 
when confluency reached 90% and were scraped down at 7 dpi when cell viability 
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decreased to approximately 80%. Infection in suspension was initiated when cell 
concentration was over 2*106 cell/ml and was terminated when cell viability dropped 
below 80%. Cell suspension was centrifuged at 3200 rpm for 5 min. Supernatant 
containing virus was collected for future infection and cellular pellet was washed twice 
with PBS (1X, GIBCO) before 10 ul of RIPA cell lysis buffer (Thermo) was added per 
1*106 cells. After 10 min on-ice incubation, 10 min centrifugation at 13200 rpm was 
performed to collect clarified cell lysate, stored at -20℃. 
 
Qualitative and quantitative test    Western blot was performed to detect the presence 
of recombinant protein in both whole cell lysate and clarified cell lysate. Standard 
molecular weight marker, Bis-Tris gel, MES SDS running buffer, transfer buffer, PVDF 
membrane, anti-his primary antibody (C-term) as well as chemiluminescent 
immunodetection kit were purchased from Invitrogen. Image developing was done with 
BIO-RAD ChemiDoc™ Imaging System with exposure time starting at 30s to as long as 
300s. Clarified cell lysate samples showing high expression were purified and desalted 
following manufacture’s protocol with HisPur™ Cobalt Purification Kit (Thermo) and 
Zeba™ Spin Desalting Column (Thermo). Western blot was also performed with purified 
and desalted samples. Concentration of total proteins was measured by Pierce BCA 
Protein Assay (Thermo) and the percentage of E2T4G was determined by Agilent High 
Sensitivity Protein 250 Kit (Agilent Technologies) thus the exact concentration of E2T4G 
could be calculated. 
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3.3 Results 
3.3.1 Cell culture in Monolayer and Suspension 
 Unlike most mammalian cells, Sf9 cells adhere weakly to T-25/75 flasks and get 
dislodged easily. It is normal that some floating cells could be observed under inverted 
microscope especially when flask was moved, rocked or the confluency of monolayer 
increased above 100%. However, too many floating cells in the event of overnight 
incubation after thawed and transferred to T-25 flask or confluency lower than 100%, still 
indicate unhealthy cell state. Cells of low passage number (< p.20) replicated faster, 
usually taking three days to reach 100% in a T-25 flak after seeding at a number of 1*106 
and two to three days to fully grow in a T-75 flask after splitting at a ratio of 1/3. Cells of 
high passage number (> p.26) took longer to multiply, nearly twice of what was needed 
by those of low passage number. Based on practice, at 100% confluency the total number 
of cells in a T-75 flask fluctuated around 4.5*107 and corresponding concentration was 
around 3*106 cell/ml, in a volume of 15 ml of media. Counting with hemocytometer for 
culture in monolayer required cells to be scraped down, therefore shear force applied to 
cells decreased viability to approximately 93% and clumps of cells led to inaccuracy in 
calculation.  
 Culture in suspension was then adapted to replace growing with T-75 flasks due to 
many disadvantages of the latter. Cells grew to 100% confluency in a T-75 flask was still 
needed to initiate culture in a 250-ml conical glass flask at a concentration of 1*106 
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cell/ml in a total volume of 30 ml of grow media. Cells with low passage number 
multiplied quickly and took two days to reach 2*106 cell/ml when they need to be 
transferred to a 500-ml flask where an additional two days were usually necessary for 
growing back to 2*106 cell/ml. Cell viability observed was higher than that in monolayer, 
being around 99%-100%. A typical growth curve is provided in figure 1. 
 
3.3.2 Infection with Recombinant Baculovirus 
 Cells growing in monolayer were infected when confluency reached 90% by directly 
adding virus stock or medium containing virus particle which was collected from a 
previous protein production with a MOI ranging from 0.1 to 5. No conspicuous 
cytopathic effect could be observed in the first two to three-day post infection except that 
nuclei might appear to be enlarged due to virus replication. The most obvious cytopathic 
effect is elevated dislodging of cells from monolayer compared to non-infected group, 
occurring as early as 3 dpi and culminating at 7 dpi when more than 80% cells floated in 
the medium. Harvest was done at 3/4/5/6/7/8 dpi and only cell pellets were kept. Grow 
media were discarded after centrifugation. Proteins were extracted by adding lysis buffer 
to cell pellets and both cell lysate and clarified cell lysate were tested by Western blot 
(WB) for the expression of recombinant. The highest expression of E2T4G was achieved 
at 7 dpi with cell viability around 85% and a total concentration around 2*106 cell/ml.  
 Infection in suspension was done with the same MOI by directly adding virus stock 
or medium from a previous infection. After infection, cell concentration still increased 
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from 2*106 cell/ml to approximately 4*106 cell/ml during the first three days. Significant 
decrease in viability was not observed until 3 dpi when 96% were alive following by 90% 
at 4 dpi and 80% at 5 dpi. A large decrease in viability from 80% to 40%-60% would be 
observed if not harvested which would cause a tremendous loss of target protein. A 
typical growth curve is shown in figure 2. 
 For both of the two growths, non-typical growth state/curve inconsistent with the 
description above was also observed, reflected by higher cell density (> 2*106 cell/ml) at 
expansion or infection time point or higher viability (> 80%) at harvest day, which might 
be attributed to different cell passages, inaccurate cell counting and temperature 
fluctuation. 
 Comparison of different parameters between culture in monolayer and suspension is 
shown in Table 1. Advantages of production with growth in suspension include reduced 
consumption of medium, flasks, labor work and risk of contamination as well as 
increased cell viability. 
 
3.3.3 Protein Extraction, Purification and Identification 
Western blot was performed according to manufacturer’s protocol. Bands of 
molecular weight marker and target protein were recognizable as early as 30-second 
exposure with ChemiDocTM Imaging System (BIO-RAD). Band of target protein E2T4G 
lies around 50 kDa instead of 55 kDa as the case of wild type E2 protein. Such reduction 
in size might be attributed to the deletion of transmembrane domain. Different from 
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clarified cell lysate, whole cell lysate exhibited an additional band around 40 kDa. These 
peptides also had his-tag but were of different molecular weight, indicating more than 
one version of E2T4G was synthesized which could be variously glycosylated proteins or 
other non-specific proteins. Some E2T4G appeared to lost during centrifugation too, 
leading to a slightly weaker band corresponding to that of whole cell lysate (figure 3A).  
It was observed that whole cell lysate was much more viscous than clarified cell 
lysate, as a result of which the former was extremely difficult to load into the gel well for 
WB and band shown after image developing, though intensity being higher, was not as 
sharp compared to clarified lysate. An explanation is that high concentration of protein 
contributes to the viscidity of sample.  
 Purified samples lost considerable proportion of target protein, reflected by much 
weaker band in WB image. Proteins were eluted from purification column three times 
with elution 2 usually having the strongest band. Desalting was performed to further 
increase purity but a conspicuous loss of protein was unavoidable (data not shown).  
 BCA assay was done to measure the concentration of total proteins in purified and 
desalted products. Elution 1 of purified sample shown the highest concentration, with 
elution 2, 3 and desalted product showing a gradual decrease. Data are provided in table 
2. Given the fact that non-specific proteins were synthesized and they might all contain a 
‘his-tag’, in order to determine the comparatively accurate percentage of E2T4G, protein 
on-chip electrophoresis was performed. Proportion of each protein component was 
readable with bio-analyzer. By comparing to a highly purified positive control which was 
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a different recombinant viral E2 produced using the same expression system is our lab 
previously. Considering both the concentration of total proteins in the solution and the 
percent of E2T4G, its actual concentration could be calculated (table 2). Schematic 
picture of E2T4G is shown in figure 5. 
A typical result of on-chip protein electrophoresis is shown in figure 4. Molecular 
weight of a band cannot be simply determined based on ladder because the ladder is 
computer generated and only represents the migration speed. Instead, by comparing to the 
positive control, if similar pattern was observed, the sample would be considered of good 
quality. Each peak represents one protein component and height of the peak indicates the 
relative amount, which means samples exhibiting few and high peaks and were purer. 
Elution 1, 2 and 3 all contained many different kinds of non-specific proteins and the 
proportion believed to be E2T4G is respectively 15%, 21.6% and 20% (table 2, figure 4). 
Desalting process further excluded non-specific proteins but recovery was low, therefore 
desalted elution 3 had higher purity (figure 4) but almost 60% of protein was lost (table 
2). 
 
3.4 Discussion 
 Previous research and manufacturer’s protocol validate the feasibility of adapting 
suspension culture for Sf9 cell growth. The exploration on growth conditions took 
months and ultimately exhibited conspicuous superiority to monolayer culture (table 1). A 
typical round of production using adherent culture required thirty T-75 flasks but actually 
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another fourteen flasks were needed to finally generate thirty. Considering 15 ml growth 
media was added to each flask, an entire volume of 660 ml media was needed. Therefore, 
culture in suspension is much more efficient and largely reduces labor work, 
consumptions and risk of contamination. In addition, without shear force applied to cells 
when they were scraped down, those growing in suspension exhibited much higher 
viability, nearly 100%, which was desired for protein expression. Some disadvantages of 
suspension culture pointed out by previous research include forming of clumps and 
potential risk of contamination due to growth in conical flask. However, clumps of cell 
were hardly observed and contamination never occurred in my practice.  
 Infection was done at a low MOI, 0.1-5 as recommended by manufacture. In this 
research, media containing viral particles was collected and saved for next round of 
infection. If good protein expression was gained from such infection with this virus stock, 
it would also be used for following several rounds of production. Viral titration was not 
performed for these virus stocks due to unsuccessful attempts, mostly unsuccessful 
staining using neutral red. However, manufacturer’s protocol mentions that such virus 
stock typically has a pfu of 5*107 to 1*108 per milliliter. Given the number of cells 
(2*108) and volume of virus (500 ul) added in suspension when infection was initiated, 
the MOI I actually ended up using should be around 0.125-0.25 which fell into the 
recommended range. Moreover, the growth curve was consistent with this low MOI, 
reflected by a slight increasing in density and prolonged high viability within three to 
four days after infection. 
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 Though designed to lose the transmembrane domain, the recombinant E2T4G was 
not easily extracted and recovered from cells. Cell lysis buffer was used in our research to 
break Sf9 cells and release protein of interest in which case it should be dissociative. 
However, shown by Western blot, samples lost large proportion of E2T4G after 
centrifugation, indicating much was associated with cell debris. Incubation time with 
lysis buffer was increased as well as repetitive freezing and thawing was adapted for the 
purpose of breaking potential linkage between E2T4G with cell debris, but no substantial 
improvement was observed. Cellular pellet was washed with ice cold PBS and 
centrifugation after adding lysis buffer was performed at 4 ℃ laboratory with the 
intention of protecting E2T4G from degradation. Still, no apparent increase in protein 
expression was achieved. 
 Given that recombinant E2T4G undergoes glycosylation, more than one version of 
proteins were probably synthesized. Based on western blot, whole cell lysate shown an 
additional band of slightly lower molecular weight which disappeared in clarified cell 
lysate. Bio-analyzer shown that purified product elution 3 lost many non-specific proteins 
after desalting. Both the band disappeared in clarified cell lysate and peaks lost in 
desalted elution 3 might be E2T4G with different degrees of glycosylation. 
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Table 1. Comparison of Culture in Monolayer and in Suspension. 
CATEGORIES MONOLAYER SUSPENSION 
Number of T-25 flask 1 1 
Number of T-75 flask 44 4 
Volume of media 660 300 
Number of cells (harvested) 8*108 10*108 
Cell viability (prior to infection) 95% 100% 
References: (1) The number of cells that can be produced in each batch of production in 
suspension is approximately equivalent to 1/3 of that in T-75 flasks. (2) Numbers were 
selected from samples with typical growth state/curve. Exceptions were not included 
(data not shown). 
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Table 2. Quantitation of Purified and Desalted Sample. 
CATEGORY ELUTION 1 ELUTION 2 ELUTION 3 DESALTED 
Concentration 
of total protein 
(ng/ul) 
270 244 97 37 
% Percentage 
of E2T4G 
15 21.6 20 27 
Concentration 
of E2T4G 
(ng/ul) 
40.5 52.7 19.4 10 
References: (1) Elution 3 was desalted and recovery rate was significantly lower than 
expected, though purity increased. No desalting treatment was done for elution 1 or 2. 
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Figure 1. Growth curve of Sf9 cell in suspension (250-ml conical flask). (A) 
Concentration of living/dead/total cells in suspension. X-axis: hour post seeding, Y-axis: 
cell density (*106 cells/ml). (B) Cell viability based on trypan blue staining. X-axis: hour 
post seeding, Y-axis: % cell viability. 
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Figure 2. Growth curve of Sf9 cell in suspension after transferred to a 500-ml conical 
flask and infection. Infection was initiated at 72-hour after transferred by directly adding 
virus stock or medium containing virus collected from a previous round of production. 
(A) Concentration of living/dead/total cells in suspension. X-axis: hour post seeding, Y-
axis: cell density (*106 cells/ml). (B) Cell viability based on trypan blue staining. X-axis: 
hour post seeding, Y-axis: % cell viability. 
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Figure 3. Western blot of whole, clarified cell lysate and purification product. Exposure 
time was set to be 300 seconds. (A) Protein was extracted from cells growing in 
suspension. Lane 2 shows whole cell lysate, the larger band being approximately 50 kDa 
and the other being slightly below 40 kDa. Lane 1 shows the corresponding clarified cell 
lysate, with the same molecular weight as the larger band in lane 2. (B) Clarified cell 
lysate from another round of production with adherent culture was purified. Lane 1 to 
lane 3 represents elution 1 to elution 3 of purified product respectively, with the same 
weight around 50 kDa. 
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Figure 4. On-chip protein electrophoresis revealed a variety of proteins in purified and 
desalted products. (A) Gel-like picture. Ladder does not show molecular weight but 
exhibits the migration speed. Duplicates were made for each sample. E1: elution 1, E2: 
elution 2, E3: elution 3, P: positive control and D: desalted elution 3. (B) Purified product 
elution 1 still contained many non-specific proteins reflected as multiple peaks. The peak 
considered to be E2T4G is pointed out with an arrow. (C) Elution 2 contained a slightly 
higher percentage of E2T4G reflected by a higher peak. (D) In elution 3, relatively fewer 
non-specific proteins were present. The proportion of E2T4G was similar to elution 2. (E) 
Desalted elution 3 contained conspicuously fewer non-specific proteins as well as a much 
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higher percentage of E2T4G. (F) Positive control used here is a different kind of 
recombinant viral E2 protein produced in our lab previously using the same expression 
system. The purity was apparently higher than any of other E2T4G samples. (G) A typical 
running pattern of ladder with seven peaks, indicating successful on-chip electrophoresis. 
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Figure 5. Comparison of E2 and E2T4G. The only difference in recombinant viral 
glycosylated envelope protein E2 from wild type one is the mutation in WH303 epitope, 
TAVSPTTLR to TSFGMDTLR (amino acid sequence). Polyclonal antibodies generated 
by infected pigs contain those with high affinity to TAVSPTTLR epitope but in 
vaccinated pigs such antibody is missing. Antibodies against other epitopes should be the 
same in both naturally infected and vaccinated pigs. 
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CHPATER 4 
SPECIFIC AIM 2: 
MODIFICATION OF A COMMERCIALLY AVAILABLE ELISA 
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4.1 Introduction 
 ELISA detecting the presence of antibody in serum against CSFV envelope 
glycosylated protein E2 has been widely used for high-throughput screenings within 
herds due to its convenience, high sensitivity and specificity. IDEXX CSFV Ab Test is a 
commercially available ELISA kit designed for accurate detection of CSFV specific 
antibodies in serum. It is widely accepted and more importantly it is used by the USDA 
for screening and surveillance. CSFV glycosylated envelope protein E2 is coated on the 
plate by manufacture and serum will be incubated in the well either for two hours or 
overnight. Positive serum control comes with the kit and will be treated in the same way. 
Enzyme linked monoclonal antibody (anti-E2) can be added to the well after washing 
away sera. Polyclonal antibody in pig sera against E2 binding to E2 in the plate will 
block secondary monoclonal antibody from binding, thus exhibiting an inhibition rate. 
Samples giving inhibition rate higher than 40% will be considered as infection. In this 
research, recombinant E2T4G was co-incubated with pig sera in the plate with the 
intention of sequestering irrelevant antibodies (anti-E2 but not anti-303) and enriching 
anti-303 antibodies. In this setting, inhibition rates higher than 40% would still be 
considered as infection but lower ones would be regarded as vaccination. Schematic 
pictures are shown in figure 6. However, we had another expectation that in the presence 
of E2T4G, the inhibition rate of serum samples from a FT4G vaccinated animal would 
still be higher than 40% but significantly lower than in the absence of E2T4G. 
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4.2 Materials and Methods 
Vaccination and challenge    Sera tested in this research were stocked at -80℃ freezer. 
Animals were previously allocated into three groups with 4 pigs in each. Group 1 and 2 
were inoculated with 105 TCID50 FlagT4v (Holinka et al., 2009) intranasally (IN), and 
group 3 was made a mock of infection. Pigs in group 1 and group 2 were challenged IN 
with 105 TCID50 CSFV Brescia strain (BICv) (Risatti, Borca, et al., 2005) at 3 DPI and 
28 DPI respectively, along with animals in group 3. Daily clinical signs including body 
temperature were monitored throughout the experiment as previously described (Risatti, 
Holinka, et al., 2005). Peripheral blood was collected at different time points post-
vaccination and post-challenge from the anterior vena cava in EDTA-containing tubes 
(Vacutainer). Samples were preserved at -80℃ freezer for subsequent use. All 
experiments were performed in Plum Island Animal Disease Center (NY). 
 
ELISA    IDEXX CSFV Ab Test Kit was used for the detection of CSFV E2 specific 
antibody in animal sera. Test was done as recommended by manufacturer’s instructions. 
25 ul of the sample diluent and 25 ul of E2T4G were added to all wells first, then 50 ul 
positive or negative control or serum samples were added respectively. Plate was 
incubated for 2 hours. Each well was added with 100 ul conjugated after rinse using 300 
ul of wash solution. Incubation of 30 min was required before addition of substrate. 
Reaction was allowed to develop for 10 min then absorbance of the samples and controls 
was measured at 450 nm with Bio Tek ELx 808 ELISA Reader. Negative control mean = 
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(NC A450 + NC2 A450)/2, positive control mean = (PC A450 + PC A450)/2, blocking 
percentage (rate of inhibition) = (NCmean A450 - Sample A450)/NCmean A450*100. 
Sample with a calculation of blocking percentage ≥ 40% was considered positive while 
≤ 30% was considered negative. All tests were performed in Plum Island Animal 
Disease Center (NY). 
 
4.3 Results 
4.3.1 E2T4G decreased inhibition in the case of vaccination instead of infection. 
 Desalted elution 3 containing E2T4G was co-incubated with sera in ELISA plate. 
Wash steps and incubation of enzyme-linked secondary antibody were performed 
according to manufacturer’s protocol. Readings of ELISA reader was calculated for 
percentage of inhibition (figure 6) and column chart is shown in figure 7. Sera from four 
vaccinated (FlagT4v) pigs at 28 DPI revealed an inhibition rate ranging from 45% to 
62%, while in the addition of E2T4G a 10% decrease was observed and one pig (No. 10) 
exhibited inhibition lower than 40%. Sera collected at 42 DPI from six vaccinated pigs 
had an obviously higher inhibition ranging from 68% to 78% mostly attributed to further 
developed antibody response. Co-incubation of E2T4G led to an average decrease in 
inhibition of 15% but one pig (No. 16) shown no more than 5% decrease. The lowest 
inhibition rate was 52% (pig No. 13). After challenging with CSFV Brescia strain, pigs 
generated antibodies against WH303 epitope which was enriched in the presence of 
E2T4G and led to a high inhibition rate. Consistent to this, sera taken from four pigs at 
 38 
17-day post-challenge all exhibited high inhibition ranging from 72% to 88% regardless 
of addition of E2T4G. Our observation is actually consistent with our second expectation 
which is that in the presence of E2T4G, serum samples would have a lower inhibition 
rate than in the absence of E2T4G but such rate would still be higher than 40%. Because 
the serum samples taken from infected animals exhibited a very similar inhibition rate 
irrespective of the addition of E2T4G, while serum samples form vaccinated pigs showed 
clearly different inhibition rates depending on E2T4G, we conclude that adding the 
recombinant viral E2 protein E2T4G can confer DIVA capability to the commercial 
IDEXX ELISA Kit. 
 
4.4 Discussion 
 The modification we made to the commercially available IDEXX ELISA exhibited 
capability of differentiating CSFV naturally infected pigs from vaccinated ones. 
However, the inhibition rate of infected and vaccinated cohorts did not significantly differ 
and compared to manufacture’s cutoff line 40%, the 10%-15% decrease in inhibition did 
not substantially distinguish between positive and negative samples. We attribute the 
unexpected low percentage of inhibition to suboptimal ELISA protocol as well as 
insufficient amount and purity of recombinant glycoprotein E2T4G.  
 ELISA is now a widely used tool for the purpose of sensitive, specific and 
convenient detection which, however, requires much experience and well controlled 
experiment conditions. We attempted to increase inhibition rate by pre-incubating serum 
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with recombinant protein or using different combinations of diluted serum and E2T4G, 
but no significant improvement was observed (data not shown). Nevertheless, there are 
more conditions remaining to be adjusted including temperature, incubation time, volume 
of each reagent and serum or E2T4G of higher or lower dilution rate. Additionally, given 
the relative low concentration of recombinant E2T4G in the reaction, it will not be 
surprising if the anti-WH303 antibodies cannot be thoroughly adsorbed and precipitated. 
 Despite the insignificant difference in inhibition percentage, our exploration on 
making the commercial ELISA fulfill DIVA criterion is successful and our strategy is 
promising for the development of such DIVA ELISA. With this being said, more work 
will have to focus on both optimizing ELISA protocol and increasing concentration and 
purity of recombinant E2T4G. In order to obtain high amount of purified E2T4G, efforts 
can be made on redesigning protein coding sequence, improving cell culture 
methodology, adjusting protein extraction and purification process and utilizing other 
protein biosynthesis systems.  
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Figure 6. Schematic picture of traditional and modified ELISA. (A) Polyclonal antibodies 
in serum samples from an infected pig, including those with high affinity for 
TAVSPTTLR epitope, bind to E2 at the bottom, exhibiting a high inhibition rate. (B) 
Polyclonal antibodies in serum samples from a vaccinated pig, those against 
TAVSPTTLR epitope not included, can also bind to E2, exhibiting high inhibition. (C) In 
the addition of E2T4G, in serum samples from an infected pig, only antibodies against 
TAVSPTTLR epitope can block E2. (D) Addition of E2T4G sequesters antibodies in in 
serum samples from a vaccinated pig, thus showing a low/no inhibition rate.  
 
   
 
Antibody with affinity for the TAVSPTTLR epitope 
Antibody with affinity for the TSFGMDTLR epitope 
Antibody with affinity for other epitopes within E2 
Antibody with affinity for other epitopes within E2 
Enzyme linked secondary antibody 
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Figure 7. Addition of E2T4G decreased percent of inhibition in the case of vaccination 
instead of infection in preliminary trails. Control group: ELISA run without addition of 
E2T4G, test group: ELISA run in the presence of E2T4G. (A) Sera were taken from four 
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vaccinated pigs at 28 DPI. Addition of E2T4G decreased inhibition by 12%, 7%, 13% 
and 8% respectively. (B) Sera were collected from another six vaccinated pigs at 42 DPI. 
Addition of E2T4G decreased inhibition by 17%, 17%, 15%, 14%, 15% and 6% 
respectively. (C) Sera were taken from pigs at 17-day post-challenge with CSFV Brescia 
strain. Addition of E2T4G did not result in significant difference in inhibition, only 2%, 
4%, 2% and 2% respectively. 
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CONCLUSION 
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5.1 Conclusion 
 The production of recombinant CSFV glycoprotein E2 through baculovirus/insect 
cell protein expression system is successful. Growing and infecting Sf9 insect cells in 
suspension is proved in my trial to be more effective, material-saving and significantly 
less labor-intensive compared to adherent culture. The recombinant protein E2T4G was 
obtained and quantitated after protein extraction and purification. 
 The modification on commercially available ELISA, IDEXX CSFV Ab Test, meet 
our expectation as the difference in inhibition rate between infected and vaccinated pigs 
was clear and distinct.  
 In conclusion, the specific aim 1 of this research is successfully achieved and the 
result of specific aim 2 potently supports the described strategy for the future 
development of a CSFV DIVA ELISA for the FT4G vaccine candidate. 
 More work remains to be done including achieving higher concentration and purity 
of the recombinant protein E2T4G as well as improving the ELISA protocol. In order to 
produce E2T4G of better quality, codon optimization, different culture conditions, 
different extraction and purification procedures can be tried. In terms of improving 
ELISA protocol, more conditions can be explored: the order of reagents added to the 
ELISA plate, pre-incubation of E2T4G with serum samples, different incubation time of 
E2T4G with serum samples, different concentrations of E2T4G, different dilutions of 
serum samples, serum samples collected at different dpi. 
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Supplement 1. Nucleotide sequence of recombinant CSFV glycoprotein E2. 
Mellitin-E2-T4G-deltaTMR-6XHis: 
ggatcc1ATGAAATTCTTAGTCAACGTTGCCCTTGTTTTTATGGTCGTATACATTTCTTACATCTATGCGCG
G2CTAGCCTGCAAGGAAGATCACAGGTACGCTATATCAACAACCAATGAGATAGGGCTACTTGGGGCCGAAG
GTCTCACTACCACCTGGAAAGAATACAACCACAATTTGCAACTGGATGATGGGACCGTCAAGGCCATCTGC
ATGGCAGGTTCCTTTAAAGTCACAGCACTTAATGTGGTTAGTAGGAGGTATCTGGCATCATTACATAAGGA
CGCTTTACCCACTTCCGTGACATTCGAGCTCCTGTTCGACGGGACCAGCCCATTGACCGAGGAAATGGGAG
ATGACTTCGGGTTCGGACTGTGTCCGTATGATACGAGCCCTGTAGTCAAGGGAAAGTACAACACAACCTTG
TTGAATGGTAGTGCATTCTACCTAGTTTGCCCAATAGGGTGGACGGGTGTTATAGAGTGCACGagtttcgg
aatggatACTCTGAGA3ACAGAAGTGGTAAAGACCTTCAGAAGAGAGAAACCCTTTCCGTACAGAAGGGATT
GTGTGACCACTACAGTGGAAAATGAAGATCTATTCTACTGTAAATGGGGGGGCAATTGGACATGTGTGAAA
GGTGAACCAGTGACCTACACGGGGGGGCCAGTAAAACAATGCAGATGGTGTGGCTTCGACTTCAATGAGCC
TGACGGACTCCCACACTACCCCATAGGTAAGTGCATTTTGGCAAATGAGACAGGTTACAGAATAGTGGATT
CAACGGACTGTAACAGAGATGGCGTTGTAATCAGCACAGAGGGGAGTCATGAGTGCTTGATTGGTAACACA
ACTGTCAAGGTGCATGCATTAGATGAAAGACTAGGCCCTATGCCATGCAGGCCTAAGGAGATCGTCTCTAG
TGCGGGACCTGTAAGGAAAACTTCCTGTACATTCAACTACGCAAAAACTCTGAGGAACAGGTATTATGAGC
CCAGGGACAGCTATTTCCAACAATATATGCTCAAGGGCGAGTATCAGTACTGGTTTGATCTGGATGTGACC
GACCGCCACTCAGATTACTTCGCAGAAcaccatcaccatcaccattaa4gaattc1 
Reference: 1. Two restriction enzyme recognition sites (BamH1: GGATCC, EcoR1: 
GAATTC). 2. Coding sequence of signal peptide for secretion. 3. Mutagenized WH303 
epitope coding sequence. 4. (6x) His-tag coding sequence. 
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Supplement 2. Amino acid (one letter) sequence of recombinant CSFV glycoprotein 
E2. 
MKFLVNVALVFMVVYISYIYAR1LACKEDHRYAISTTNEIGLLGAEGLTTTWKEYNHNLQLDDGTVKAICMA
GSFKVTALNVVSRRYLASLHKDALPTSVTFELLFDGTSPLTEEMGDDFGFGLCPYDTSPVVKGKYNTTLLN
GSAFYLVCPIGWTGVIECTSFGMDTLR2TEVVKTFRREKPFPYRRDCVTTTVENEDLFYCKWGGNWTCVKGE
PVTYTGGPVKQCRWCGFDFNEPDGLPHYPIGKCILANETGYRIVDSTDCNRDGVVISTEGSHECLIGNTTV
KVHALDERLGPMPCRPKEIVSSAGPVRKTSCTFNYAKTLRNRYYEP RDSYFQQYMLKGEYQYWFDL 
DVTDRHSDYFAEHHHHHH3 
Reference: 1. Additional hydrophobic signal peptide for secretion. However, the 
recombinant E2 lacks terminal hydrophobic amino acid sequence (about 32 aa, not 
shown) which is believed to be the transmembrane domain. 2. Mutagenized WH303 
epitope. Five altered amino acids are S, F, G, M and D which in wild type E2 correspond 
to A, V, S, P and T respectively. 3. Six-histidine tag for detection with Western blot. 
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